Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

Related Content

FDA Clears Zohydro Single-Entity Hydrocodone Without Abuse Deterrence Properties

Oct 25 2013

Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Feb 01 2016

Keeping Track: Neurology And Pain Products Keep FDA Occupied

Aug 17 2015

RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns

Apr 06 2017

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price

Apr 06 2017

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Apr 06 2017

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

Nov 28 2016

FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock

Feb 04 2016

US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say

Mar 15 2017

Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon

Mar 22 2017

Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

Mar 28 2017

Opioid Clinical Efficacy Standards Need Rethinking, FDA Panel Says

Jun 20 2016

Related Companies

Zogenix, Inc.

Currax Pharmaceuticals LLC

Purdue Pharma L.P.

Nevro Corp.

Additional Topics

United States FDA Drug Safety Regulation BioPharmaceutical Neurology

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window